uploads///thermometer _

Depomed versus Peers in March 2018: Analyst Ratings

By

Mar. 7 2018, Updated 1:30 p.m. ET

Company overview

Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. Its special pharmaceutical business includes Gralise (for the management of postherptic neuralgia), Cambia (for the treatment of migraine attacks), and Zipsor (for the treatment of mild to moderate acute pain).

Article continues below advertisement

Analysts’ recommendations

In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. The mean rating for the stock is 2.71, with a target price of $8.43.

Peer ratings

By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating. The mean rating for the stock is 2.14, with a target price of $66.24.

Of the 23 analysts covering Pfizer (PFE) in March 2018, two analysts have given the stock a “strong buy” rating, while ten analysts have given it a “buy” rating. Nine analysts have given the stock a “hold” rating, while two analysts have given it a “strong sell.” The mean rating for the stock is 2.57, with a target price of $40.2.

Of the 15 analysts covering Impax Laboratories (IPXL) in March 2018, two analysts have given the stock a “strong buy” rating, and two analysts have given it a “buy” rating. Ten analysts have given it a “hold” rating, while one analyst has given the stock a “sell” rating. The mean rating for the stock is 2.67, with a target price of $21.69.

In the next part of the series, we’ll take a look at Depomed’s business strategy.

Advertisement

More From Market Realist